Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most difficult cancers to treat, with a dismal 5-year survival rate of only 8–10%. This challenging prognosis highlights the urgent need for innovative therapeutic approaches to improve outcomes for patients with PDAC. Electrochemotherapy (ECT), which enhances intracellular chemotherapeutic uptake via electric pulses, has been explored for resectable, borderline resectable (BR), locally advanced (LA), recurrent, and metastatic PDAC, either as a complement to conventional treatments or as an alternative when these are not feasible or effective, offering possible benefits in symptomatic palliation and local tumor control. Methods: A systematic review was performed in accordance with PRISMA guidelines for studies assessing the efficacy of ECT in PDAC. After searching Embase, PubMed/MEDLINE, Scopus, and Web of Science, five studies with a combined total of 43 patients in various disease stages were identified. Results: ECT showed promise in improving tumor control, alleviating cancer-related pain, and improving quality of life. One study noted a trend towards tumor size reduction of 8.3% at one-month and 16.1% at six-months follow-up (p = 0.211 and p = 0.315), although these findings were derived from studies conducted without specific comparative control groups. Severity of complication was mainly mild (Clavien–Dindo I-II), while severe complications occurred in only 2.3% of patients. Median overall survival was reported in two studies as 8 months (range 2–19) and 11.5 months (range 1–74). ECT showed efficacy for symptom management, with 60% of patients reporting reduced pain/discomfort and 40% showing enhanced quality of life in one study, while another reported pain scores as decreasing from 6 to 3 at one month and to 2 at six months. Conclusions: ECT appears to be a new promising and safe adjunct treatment modality in PDAC management across different disease stages, with potential benefits in tumor control, cancer-related pain reduction, and quality of life. Further studies are warranted to validate these findings and identify patients who could benefit most.
Background/Objectives: Robotic surgery has emerged as a promising alternative to traditional approaches, offering enhanced precision and ergonomics. However, its application to pancreaticoduodenectomy (PD) remains controversial due to technical complexity and a steep learning curve. This study aims to evaluate the perioperative outcomes of robotic versus open PD at a single high-volume center, using inverse probability of treatment weighting (IPTW) to control for confounding variables. Methods: A retrospective, single-center analysis was conducted on patients who underwent PD between January 2020 and December 2024. Perioperative and oncological outcomes were compared using IPTW, aiming to balance potential confounding variables. The primary endpoint was 90-day postoperative mortality; secondary endpoints included operative time, estimated blood loss, major postoperative complications (Clavien-Dindo grade ≥ IIIa), and length of hospital stay. Results: Seventy-four patients were included in the intention-to-treat analysis (open: n = 31; robotic: n = 43). After IPTW adjustment, baseline characteristics were balanced across the groups. Operative time was significantly longer in the robotic group (median 540 vs. 479 min, p = 0.009). No significant differences were observed in 90-day mortality (4.9% both groups, p = 0.998), postoperative complications ≥ IIIa, or histopathological outcomes, including R0 resection and lymph node yield. Trends toward reduced estimated blood loss and shorter hospital stay in the robotic group did not reach statistical significance. Conclusions: Robotic pancreaticoduodenectomy demonstrates comparable safety and oncological efficacy to the open approach, with longer operative times but potential perioperative advantages. These findings support the continued integration of robotic techniques even in medium-volume centers with appropriate expertise.
Locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) involving the body and neck of the pancreas often necessitates complex resections in selected cases, such as the Appleby procedure, also known as distal pancreatectomy with en bloc celiac axis resection (DP-CAR). A 75-year-old female with LA-PDAC, confirmed by endoscopic ultrasound-guided biopsy and treated with neoadjuvant chemotherapy, was initially planned for a robotic DP-CAR. During surgery, transit-time flow measurement (TTFM) showed an inverted and threefold increase in the gastroduodenal artery flow after clamping of the common hepatic artery (CHA), ensuring adequate liver perfusion and avoiding unnecessary preoperative CHA embolization to enhance collateral arterial circulation to the liver. Intraoperative findings revealed only fibrosis without evidence of tumor infiltration around the celiac axis, as confirmed by intraoperative frozen sections. This led to a shift from the planned DP-CAR procedure to an anterior radical antegrade modular pancreatosplenectomy (RAMPS). Final histopathological examinations revealed chronic pancreatitis and complete tumor regression (tumor regression grade 0, ypT0N0). This case underscores the role of robotic platforms and intraoperative tools like TTFM in real-time decision making, enabling tailored surgical strategies for complex pancreatic resections, ensuring oncological adequacy, and optimizing patient outcomes.
1 February 2026 in HepatoBiliary Surgery and Nutrition
Editorial Commentary Advancing the standard in donor hepatectomy: reflections on pure laparoscopic donor right hepatectomy and the evolving role of minimally invasive approaches Roberto I. Troisi, Giuseppe Loiaco, Mariano Cesare Giglio, Gianluca Rompianesi, Roberto Montalti
Chronic pancreatitis (CP) is a progressive inflammatory disease characterized by debilitating pain and exocrine insufficiency. When medical and endoscopic treatments fail, surgical decompression may be required. The Partington-Rochelle procedure, a well-established option for ductal decompression via pancreaticojejunostomy, is traditionally performed through open surgery. While the laparoscopic approach is technically challenging, robotic-assisted surgery offers enhanced precision, reduced trauma, and faster recovery. We present the case of a 45-year-old male with CP, recurrent pseudocyst formation, and persistent symptoms despite medical and endoscopic treatment. The patient underwent a robotic Partington-Rochelle procedure using the Da Vinci Xi system. The procedure was successfully completed in 240 min with and an estimated blood loss of 150 mL. Postoperative recovery was uneventful, and the patient was discharged on postoperative day 7 with no complications. At the 3-month follow-up, symptoms had completely resolved, and cyst size had decreased. At 30 months, the patient remained asymptomatic and no longer required analgesics. MRI showed stable pancreatic parenchyma with reduced cystic lesions, and fecal elastase levels indicated mild pancreatic insufficiency. This case highlights the feasibility and effectiveness of the robotic Partington-Rochelle procedure for CP management. The robotic approach provides superior visualization and precision, enabling optimal ductal decompression while overcoming the limitations of laparoscopic and open techniques. Compared to traditional open surgery, it offers faster recovery, reduced morbidity, and excellent long-term symptom control, making it a promising alternative for selected patients.